Cover illustration
Photomicrograph of normal peripheral blood (small cells) which form conjugates with the human NC tumor target BT-20 (human breast carcinoma). These cells are stained with Wrights Giemsa and show intimate association between the tumor and PBL. Photomicrograph provided through the courtesy of Drs. Antonella Stopacciaro and Edmund C. Latime, Laboratory of Cellular Immunology, Sloan-Kettering Cancer Center, New York, NY, USA.

Library of Congress Cataloging-in-Publication Data
Immunomodulation of neoplasia.
(Progress in experimental tumor research; vol. 32)
Includes bibliographies and index.
ISBN 3-8055-4595-9

Bibliographic Indices
This publication is listed in bibliographic services, including Current Contents® and Index Medicus.

Drug Dosage
The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.
No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Contents

Cruse, J.M.; Lewis, R.E., Jr. (Jackson, Miss.): Cellular and Cytokine Immunotherapy of Cancer 1
Urban, J.L.; Schreiber, H. (Chicago, Ill.): Host-Tumor Interactions in Immunosurveillance against Cancer 17
Fujiwara, H.; Hamaoka, T. (Osaka): Cellular Mechanisms of Tumor Rejection in vivo and Enhanced Induction of Anti Tumor Protective Immunity Applicable to Tumor-Specific Immunotherapy 69
Wiltrout, R.H. (Frederick, Md.); Salup, R.R. (Pittsburgh, Pa.): Adoptive Immunotherapy in Combination with Chemotherapy for Cancer Treatment 128
Talmadge, J.E. (Frederick, Md.): Therapeutic Potential of Cytokines: A Comparison of Preclinical and Clinical Studies 154
Rossio, J.L.; Ruscetti, F.W. (Frederick, Md.): Immunomodulation of Neoplasia by Interleukin 2 174
Forni, G.; Cavallo, G.P.; Giovarelli, M.; Benetton, G.; Jemma, C.; Barioglio, M.G.; De Stefani, A.; Forni, M. (Turin); Santoni, A.; Modesti, A. (Rome); Cavallo, G.; Menzio, P.; Cortesina, G. (Turin): Tumor Immunotherapy by Local Injection of Interleukin 2 and Non-Reactive Lymphocytes. Experimental and Clinical Results 187
Yagita, M.; Grimm, E.A. (Houston, Tex.): Current Understanding of the Lymphokine-Activated Killer Cell Phenomenon 213
Ledbetter, J.A.; Hellström, I.; Lovoll, G.; Tsu, T.T.; Hellström, K.E. (Seattle, Wash.): Stimulation of Lymphocyte Function by Monoclonal CD2 (E Rosette Receptor-Specific Antibodies 227
Subject Index 239